Results 91 to 100 of about 40,708 (270)
Narcolepsy and rapid eye movement sleep
Journal of Sleep Research, Volume 34, Issue 2, April 2025.Summary Since the first description of narcolepsy at the end of the 19th Century, great progress has been made. The disease is nowadays distinguished as narcolepsy type 1 and type 2. In the 1960s, the discovery of rapid eye movement sleep at sleep onset led to improved understanding of core sleep‐related disease symptoms of the disease (excessive ...
Francesco Biscarini +4 more
wiley +1 more source
Impact of Continuing Education on Clinicians' Self- Reported Knowledge of Tobacco Dependence and Tobacco Control Interventions [PDF]
, 2018 Purpose: To assess a tobacco cessation continuing education (CE) program for Indiana dental and medical providers. Methods: A 26-item immediate post-CE survey and a 19-item 3-month follow-up survey assessed changes in participants’ self-reported ...
Coan, Lorinda, Romito, Laura M.
core
Journal of Sleep Research, Volume 34, Issue 2, April 2025.Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont +5 more
wiley +1 more source
Psychiatry and Clinical Psychopharmacology, 2021 Objective: The most effective aproach to individuals who wants to and decided to stop cigarettes smoking is behavior training with the application of motivational support and pharmacological therapy. This study aims to compare the effects of varenicline,
Selma Bozkurt Zincir +3 more
doaj
Antidepressant Use and Depressive Symptoms in Intensive Care Unit Survivors [PDF]
, 2017 Nearly 30% of intensive care unit (ICU) survivors have depressive symptoms 2-12 months after hospital discharge. We examined the prevalence of depressive symptoms and risk factors for depressive symptoms in 204 patients at their initial evaluation in the
Boustani, Malaz +8 more
core +1 more source
Neurogastroenterology &Motility, EarlyView.DGBI symptoms are common in obesity and have the potential to exacerbate negative health outcomes. In general, the prevalence of DGBI symptoms decreases after obesity treatment, but patients can also shift from one GI symptom profile to another. ABSTRACT Background & Aims Disorders of gut‐brain interaction (DGBI) in obesity could impair health outcomes.
Esther Colomier +11 more
wiley +1 more source
Substance Abuse: Research and Treatment, 2012 Bupropion's (Zyban ® SR) effectiveness to treat symptoms experienced in marihuana withdrawal was tested in a double-blind, placebo-controlled study with chronic, heavy marihuana users.
David M. Penetar +4 more
doaj +1 more source
Methylphenidate, Bupropion, and SSRI Triple Therapy [PDF]
, 2012 Methylphenidate and bupropion have been demonstrated as being effective adjuncts to serotonin reuptake inhibitors in the treatment of depression (1,2). The use of these medications in case of a depressed patient whose condition was resistant to several ...
Bobo, William, M.D.
core +1 more source
Continuous Theta Burst to Supplementary Motor Area Modulates Groove
Annals of the New York Academy of Sciences, EarlyView.ABSTRACT The pleasurable urge to move to music (“groove”) has been shown to be greatest for moderately complex musical rhythms. This is thought to occur because temporal predictions from the motor system reinforce our perception of the beat when there is a balance between expectation and surprise.
Connor Spiech +3 more
wiley +1 more source
Potentiation of Antidepressant Effects of Agomelatine and Bupropion by Hesperidin in Mice
Neurology Research International, 2018 Hesperidin, a well-known flavanone glycoside mostly found in citrus fruits, showed neuroprotective and antidepressant activity. Agomelatine, a melatonergic MT1/MT2 agonist and 5-HT2C receptor antagonist, exhibits good antidepressant efficacy.
Jegan Sakthivel Nadar +4 more
doaj +1 more source